INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials ...

No other previous therapy for advanced breast cancer was permitted. Patients with visceral crisis, symptomatic or untreated brain metastases, or inflammatory breast cancer were excluded.

On May 15, 2025, the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib ...

Women with advanced breast cancer who progress on prior CDK4/6 inhibition can still benefit from second-line treatment with a CDK4/6 inhibitor as part of combination therapy.

Across the pooled Enhertu and comparator populations with and without brain metastases, anywhere from 49.4% to 68.1% of patients had recurrent breast cancer. Additionally, anywhere from 70.9% to 96.6% ...